Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.